September 12, 2025

Celcuity Inc. (CELC) Stock Analysis: Biotechnology Innovator with Strong Buy Ratings and 20.89% Upside Potential

Celcuity Inc. (NASDAQ: CELC), a burgeoning player in the biotechnology sector, has captured the attention of investors with its innovative approach to cancer treatment and a promising stock outlook. This..

Cel-Sci Corporation (CVM): Investor Outlook on a Biotech Play with Over 1,700% Potential Upside

Cel-Sci Corporation (NASDAQ: CVM), a clinical-stage biotechnology company, has captured investor attention with its staggering potential upside of 1,731.28%. With a market capitalization of $78.57 million and a current stock..

Personalis, Inc. (PSNL) Stock Analysis: Navigating a 15.78% Upside Potential Amidst a Challenging Landscape

Personalis, Inc. (PSNL) is carving out a niche in the healthcare sector, specifically in the diagnostics and research industry. This Fremont, California-based company focuses on the cutting edge of cancer..

Delcath Systems, Inc. (DCTH) Investor Outlook: Exploring a Promising 118% Upside in the Medical Devices Sector

Delcath Systems, Inc. (NASDAQ: DCTH), a healthcare player in the medical devices industry, is turning heads with its robust growth potential and a compelling upside forecast. With a market capitalization..

Collegium Pharmaceutical, Inc. (COLL) Stock Report: A 14% Upside Potential with Strong Revenue Growth

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) stands out in the healthcare sector, specifically within the drug manufacturers’ niche focusing on specialty and generics. With its market cap of $1.23 billion, Collegium..

Oculis Holding AG (OCS) Stock Analysis: Biotechnology Innovator with a 119% Upside Potential

Oculis Holding AG (NASDAQ: OCS), a prominent player in the biotechnology sector, is capturing investor attention with its promising pipeline of ophthalmic drug candidates and a potential upside of 119.03%...

Septerna, Inc. (SEPN) Investor Outlook: Exploring a 68% Potential Upside in Biotech

Investors looking for promising opportunities in the biotechnology sector should consider Septerna, Inc. (NASDAQ: SEPN). Based in South San Francisco, California, Septerna is a clinical-stage biotech company dedicated to developing..

Mind Medicine (MNMD) Investor Outlook: Analyzing the 159% Potential Upside

Mind Medicine (MindMed) Inc. (MNMD), a burgeoning player in the healthcare sector, is capturing investor attention with its promising potential upside. Positioned in the biotechnology industry, this New York-based clinical-stage..

GH Research PLC (GHRS) Investor Outlook: Exploring a Promising 162.99% Upside

For investors with an eye on the burgeoning biotechnology sector, GH Research PLC (NASDAQ: GHRS) presents a compelling opportunity. With a market capitalization of $774.13 million, this Dublin-based biopharmaceutical company..

Spyre Therapeutics, Inc. (SYRE): Analyst Consensus Points to a 232.72% Upside Potential

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company, is drawing significant investor attention with its promising pipeline and compelling market potential. Focused on developing innovative therapeutics for inflammatory bowel..

Theravance Biopharma, Inc. (TBPH) Stock Analysis: Unveiling a 34% Potential Upside for Investors in the Biotech Sector

Theravance Biopharma, Inc. (NASDAQ: TBPH) stands as an intriguing opportunity within the biotechnology sector, not just for its robust revenue growth but also its potential upside of 34.31%. Here’s a..

ATAI Life Sciences N.V. (ATAI) Investor Outlook: 145% Potential Upside in Biotech Space

Investors with an appetite for high-growth opportunities in the biotech sector may find ATAI Life Sciences N.V. (NASDAQ: ATAI) particularly intriguing. The Germany-based clinical-stage biopharmaceutical company is making waves with..

REGENXBIO Inc. (RGNX): Analyst Ratings Highlight a Promising 213% Upside Potential

REGENXBIO Inc. (NASDAQ: RGNX) is making waves in the biotechnology sector, capturing the attention of investors with its promising pipeline and impressive analyst ratings. Despite facing some financial challenges, the..

Cullinan Therapeutics, Inc. (CGEM): Exploring a 296% Upside Potential in Biotech

Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a clinical-stage biopharmaceutical firm, is garnering significant investor interest with its promising pipeline of therapies targeting autoimmune diseases and cancer. Headquartered in Cambridge, Massachusetts, the..

Cronos Group Inc. (CRON) Stock Analysis: Navigating Market Challenges with Promising Revenue Growth

Cronos Group Inc. (NASDAQ: CRON), a prominent player in the global cannabinoid market, has been capturing investor attention with its recent financial performance and market positioning. With a market capitalization..

Iovance Biotherapeutics, Inc. (IOVA): Exploring a 276% Potential Upside in the Biotech Sector

For investors with an eye on the healthcare sector, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) presents a compelling opportunity in the biotechnology industry. With a market capitalization of $875.69 million, Iovance..

Opthea Limited (OPT)

⚠️ No article content returned.

..

Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: A Deep Dive into its 139% Potential Upside

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) stands at the forefront of biotechnology with a mission to revolutionize the treatment of rare and devastating diseases through its innovative gene therapy programs. As..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: Biotechnology Innovator with 25% Upside Potential

Maze Therapeutics, Inc. (NASDAQ: MAZE) has recently been catching the attention of investors, thanks to its strong potential upside and promising pipeline in the biotechnology sector. Specializing in precision medicines..

LifeMD, Inc. (LFMD) Stock Analysis: Potential Upside of Over 118% for Investors

LifeMD, Inc. (NASDAQ: LFMD), a burgeoning player in the healthcare sector, stands out as a unique investment opportunity, particularly for those interested in the dynamic world of telehealth. With a..

Search

Funds

September 12, 2025

Search

Funds

September 12, 2025

FTSE 100

Funds